GoodRx Holdings, Inc. (NASDAQ:GDRX) Short Interest Update

Key Points

• Short interest fell 15.8% in March to 9,212,055 shares, representing 2.8% of shares short and a days-to-cover ratio of about 2.2 based on average volume.
• GoodRx reported quarter EPS of $0.09 (in line with estimates) and revenue of $194.79M (down 1.9% YoY); the stock opened at $1.94, has a market cap of ~$664.6M and a 52-week range of $1.77–$5.81.
• Analysts are mixed: the consensus rating is Hold with a $3.98 target (5 Buys, 8 Holds, 3 Sells), and several firms recently lowered their price targets.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) was the target of a large decline in short interest during the month of March. As of March 13th, there was short interest totaling 9,212,055 shares, a decline of 15.8% from the February 26th total of 10,935,571 shares. Currently, 2.8% of the shares of the stock are short sold. Based on an average trading volume of 4,115,761 shares, the days-to-cover ratio is currently 2.2 days.

GoodRx Stock Performance

Shares of GDRX opened at $1.94 on Monday. The company has a market capitalization of $664.59 million, a PE ratio of 21.56, a PEG ratio of 1.34 and a beta of 1.52. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.61 and a current ratio of 2.61. The company's 50 day moving average price is $2.27 and its 200 day moving average price is $2.96. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its earnings results on Wednesday, February 25th. The company reported $0.09 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.09. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. The company had revenue of $194.79 million during the quarter, compared to the consensus estimate of $193.27 million. During the same quarter in the prior year, the firm earned $0.09 EPS. The company's revenue was down 1.9% compared to the same quarter last year. Research analysts expect that GoodRx will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. LSV Asset Management lifted its holdings in shares of GoodRx by 517.1% during the 3rd quarter. LSV Asset Management now owns 2,354,581 shares of the company's stock valued at $9,960,000 after buying an additional 1,973,017 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in GoodRx in the third quarter worth approximately $3,036,000. Pacer Advisors Inc. acquired a new position in GoodRx in the third quarter worth approximately $3,687,000. Jefferies Financial Group Inc. acquired a new position in GoodRx in the second quarter worth approximately $132,000. Finally, Pathway Capital Management LP raised its position in GoodRx by 69.0% during the third quarter. Pathway Capital Management LP now owns 986,158 shares of the company's stock valued at $4,171,000 after acquiring an additional 402,721 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Barclays began coverage on GoodRx in a report on Monday, December 8th. They set an "underweight" rating and a $3.00 target price for the company. Citigroup dropped their price target on GoodRx from $4.50 to $3.50 and set a "buy" rating on the stock in a research note on Tuesday, March 3rd. Mizuho cut their price objective on GoodRx from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Friday, February 27th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of GoodRx in a research note on Tuesday, December 23rd. Finally, Wall Street Zen cut shares of GoodRx from a "buy" rating to a "hold" rating in a report on Sunday, January 25th. Five research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $3.98.

GoodRx Company Profile

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.